Hypersensitivity reactions to IL-1 and IL-6 inhibitors are linked to common HLA-DRB1*15 alleles

Jill Hollenbach[1]*, Michael J. Ombrello[2]*, Adriana Tremoulet[3], Jaime S. Rosa Duque[4], Gilbert T. Chua[4], Gonzalo Montero-Martin[5], Jane C. Burns[3], Chisato Shimizu[3], Gail Deutsch[6], Dimitri Monos[7], Vamsee Mallajosyula[5], Jianpeng Xu[5], Debopam Ghosh[5], Serena Tan[5], Elaine Remmers[8], Scott Canna[9], Ann Marie Szymanski[2], Danielle Rubin[2] Marcelo A. Fernandez-Vina[5], Vivian E. Saper[5]**, Elizabeth D. Mellins[5]** and the Drug Hypersensitivity in sJIA Consortium investigators***

[1]University of California San Francisco, San Francisco, CA
[2]National Institute of Musculoskeletal and Skin Diseases, Bethesda, MD
[3]University of California San Diego, San Diego, CA
[4]University of Hong Kong, Hong Kong
[5]Stanford University, Stanford, CA
[6]University of Washington, Seattle, WA
[7]University of Pennsylvania, Philadelphia, PA
[8]National Human Genome Research Institute, Bethesda, MD
[9]University of Pittsburgh, Pittsburgh, PA

*Drs. Hollenbach and Ombrello are co-first authors of this work.
**Correspondence to either mellins@stanford.edu or vesaper@stanford.edu
*** A list of members of the Consortium is provided in the *Supplementary Appendix*.

ABSTRACT

In Saper et al (2019), we described systemic JIA patients who developed a high-fatality diffuse lung disease (DLD) while on IL-1 or IL-6 inhibitors. We observed severe delayed drug hypersensitivity reactions (DHR) in a significant subset. Because alleles of the human leukocyte antigen (HLA) loci can mediate DHR, we investigated HLA genotype association with these DHR. We typed subjects treated with these inhibitors: 34 sJIA/DHR/DLD, 11 sJIA/DHR without DLD, 18 drug-tolerant sJIA, and 19 Kawasaki disease (KD) patients in an anti-IL-1(anakinra) trial. We also accessed genotypes from a large sJIA case/control cohort.

We first compared White subjects with sJIA/DHR to 550 ancestry-matched sJIA subjects. We found striking enrichments of HLA-DRB1*15:01, HLA-DQA1*01:02, and DQB1*06:02, alleles in near-complete linkage (White individuals). HLA-DRB1*15:01 (as haplotype proxy) was increased in White sJIA subjects with DHR/DLD versus sJIA drug-tolerant controls and was observed upon inclusion of sJIA+DHR-only and KD+DHR White subjects. In our entire cohort regardless of ancestry, 75% carried HLA-DRB1*15:01 or the structurally related DRB1*15:03 and DRB1*15:06, which were absent among drug-tolerant subjects ($p=5 \times 10^{-13}$; Odds Ratio lower bound=20.11).

Patients who harbor HLA-DRB1*15 alleles are at high risk of developing DHR to anti-IL-1/IL-6. Our data also suggest DHR maybe a trigger/enhancer of DLD in sJIA patients and support performing prospective HLA screening in sJIA, its adult-onset counterpart, and other inflammatory conditions where these drugs are used, such as KD.

Severe delayed hypersensitivity reactions (DHR) are observed to various drugs that are otherwise highly efficacious. Particular *human leukocyte antigen (HLA)* class I and/or class II alleles are associated with DHR risk for particular drugs, allowing screening of patients to inform clinical decision making.

Recently, we observed drug-related eosinophilic systemic syndrome (DReSS), a form of DHR, in children with systemic juvenile idiopathic arthritis (sJIA), complicated by a novel, parenchymal, diffuse lung disease (DLD).[1] The lung pathology was a variant of pulmonary alveolar proteinosis (Figure S1a, b), and DHR features included drug eruptions (Figure S1c-h) and eosinophilia. The implicated drugs were IL-1 and IL-6 inhibitors. To determine whether risk of this DHR was HLA-associated, we accessed genotypes from a large, multi-ethnic sJIA case/control cohort[2] and from 34 sJIA subjects with DLD/DHR, 11 with DHR without DLD, and 18 carefully screened, drug-tolerant sJIA controls. Methods, ancestry/*HLA* data (Table S1) and additional information on clinical features (Table S2, S3) are in *Supplementary Appendix.*

We first compared White subjects in the sJIA/DHR/DLD subgroup to 550 ancestry-matched (Fig. S2) sJIA subjects without known DLD and to 3279 ancestry-matched healthy controls.[2] We found conspicuous enrichments for *HLA-DRB1*15:01*, *HLA-DQA1*01:02* and *HLA-DQB1*06:02* (Tables 1A, S4), alleles in near-complete linkage in White individuals. Using White sJIA/all-DHR cases increased this haplotype-associated risk, linking it to DHR, as opposed to DLD. As expected, *HLA-DRB1*11/HLA-DQB1*03:01*, the sJIA-associated haplotype[2], was present in sJIA cases with and without DHR (Table S4).

Using *HLA-DRB1*15:01* as a haplotype proxy, we found a high frequency (75%) of this allele in White sJIA subjects with DHR with or without DLD vs 0% in drug-tolerant controls (Table 1B). To determine whether *HLA*-linked DHR required sJIA-specific immune dysfunction, we studied a small cohort (n=19) of children with Kawasaki disease (KD) in a Phase I/IIa trial of anakinra. Including White KD subjects with/without suspected anakinra reaction (sAR) yielded the same striking results (Table 1B).

The addition of Non-White cases provided 49 subjects with DHR, of which a remarkable 37 carried *HLA-DRB1*15:01* or the closely related **15:03* and **15:06*; this allelic group was completely absent among drug-tolerant controls (Table 1B). Notably, *HLA-DRB1*15:02*, which differs from *HLA-DRB1*15:01* by one amino acid that influences peptide-binding (Fig S3), was not associated with DHR. Analysis of the sJIA-DHR/KD-sAR group across ancestries, where patterns of linkage disequilibrium differ, suggested the operative locus is *HLA-DRB1*, as we find reduced effect for alleles at other loci on this haplotype (Table 1B).

An unusual aspect of this DHR/HLA association is that the risk spans several inhibitors with different chemical structures (Figure S4). These findings raise the possibility that an excipient common to these drugs and/or a molecule increased by inhibition of the IL-1/IL-6 network (Figure S5) creates a stimulatory HLA class II molecule, which activates CD4+ T cells. The immune dysregulation in sJIA and KD likely underlies the failure to restrain this T cell response.[3]

Our findings highlight the need for surveillance for DReSS to IL-1/IL-6 inhibitors, which is often missed, especially when it occurs during active systemic inflammatory disease. Importantly, DHR in sJIA may initiate or substantially contribute to DLD (Table S2). Carriers of the risk alleles are common [27% (White), 15% (Hispanic), 27% (Black) and 16% (Asians) in US populations].[4] Our results argue for consideration of prospective *HLA* screening in sJIA and its adult-onset counterpart. For other emergent inflammatory conditions for which these drugs are used, including COVID-19 and MIS-C, eosinophil and atypical lymphocyte counts should be monitored.[5]

References

1. Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. *Ann Rheum Dis* 2019;78(12):1722-31. doi: 10.1136/annrheumdis-2019-216040
2. Ombrello MJ, Remmers EF, Tachmazidou I, Grom A, Foell D, Haas J-P, Martini A, Gattorno M, Ozen S, Prahalad S, Zeft AS, Bohnsack JF, Mellins ED, et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis, *Proc Natl Acad Sci U S A.* 2015 Dec 29;112(52):15970-5.
3. Naisbitt DJ, Olsson-Brown A, Gibson A, et al. Immune dysregulation increases the incidence of delayed-type drug hypersensitivity reactions. *Allergy*. 2020;75(4):781-797. doi:10.1111/all.14127
4. Gragert L, Madbouly A, Freeman J, Maiers M. Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. *Hum Immunol*. 2013;74(10):1313-1320.
5. Abdin SM, Elgendy SM, Alyammahi SK, Alhamad DW, Omar HA. Tackling the cytokine storm in COVID-19, challenges and hopes [published online ahead of print, 2020 Jul 11]. *Life Sci*. 2020;257:118054. doi:10.1016/j.lfs.2020.118054

TABLE 1. *HLA* class II associations with delayed drug hypersensitivity to IL-1 and IL-6 inhibitors

Comparison		Ancestry	HLA allele[1]	Case n(%)	Control n(%)	*P* value	OR	95% CI
Case	**Control**							
A.								
sJIA-DHR/DLD[2]	INCHARGE sJIA[3]	European[4]	*HLA-DRB1*15:01*	11/12 (92%)	130/550 (24%)	7.0E-07	36	4.5-277.9
			*HLA-DQB1*06:02*	11/12 (92%)	128/550 (23%)	6.0E-07	36	4.6-283.6
			*HLA-DQA1*01:02*	11/12 (92%)	188/550 (34%)	3.0E-05	21	2.7-165.3
sJIA: all DHR[5]			*HLA-DRB1*15:01*	13/14 (93%)	130/550 (24%)	4.0E-08	42	5.4-324.1
			*HLA-DQB1*06:02*	13/14 (93%)	128/550 (23%)	4.0E-08	43	5.6-330.8
			*HLA-DQA1*01:02*	13/14 (93%)	188/550 (34%)	5.0E-06	25	3.2-192.8
B.								
sJIA-DHR/DLD	drug tolerant sJIA[6]	White/ European[7]	*HLA-DRB1*15:01*	14/18 (78%)	0/11 (0%)	5.0E-05	Inf	5.21-Inf
sJIA: all DHR	drug tolerant sJIA		*HLA-DRB1*15:01*	18/24 (75%)	0/11 (0%)	3.0E-05	Inf	5.12-Inf
sJIA-DHR+KD-sAR[8]	drug tolerant sJIA+KD[9]		*HLA-DRB1*15:01*	19/26 (73%)	0/12 (0%)	2.0E-05	Inf	5.32-Inf
sJIA-DHR/DLD	drug tolerant sJIA	All[10]	*HLA-DRB1*15:XX*[11]	26/34 (76%)	0/18 (0%)	4.0E-08	Inf	10.45-Inf
sJIA: all DHR	drug tolerant sJIA		*HLA-DRB1*15:XX*	34/45 (76%)	0/18 (0%)	1.0E-08	Inf	10.69-Inf
sJIA-DHR+KD-sAR	drug tolerant sJIA+KD		*HLA-DRB1*15:XX*	37/49 (76%)	0/33 (0%)	3.0E-13	Inf	20.70-Inf
			*HLA-DRB5*01:01*	25/31 (80%)	1/27 (4%)	9.0E-10	95.41	11.7-4460.5
			*HLA-DQB1*06:02*	34/49 (69%)	1/33 (3%)	2.0E-10	73.12	10.3-3189.8
			*HLA-DQA1*01:02*	37/47 (79%)	7/33 (21%)	3.0E-07	13.16	4.14-47.65

OR, odds ratio; 95% CI, 95% confidence interval; sJIA, systemic juvenile idiopathic arthritis; KD: Kawasaki disease; DHR: delayed hypersensitivity reaction; diffuse lung disease (DLD); sAR; suspected anakinra reaction (delayed type, not anaphylaxis).

[1]HLA class I typing was also done on a large proportion of the subjects, but did not show any independent associations (not shown)

[2]sJIA-DHR/DLD: cases with sJIA, delayed hypersensitivity reaction (DHR) and diffuse lung disease (DLD)

[3] INCHARGE sJIA: sJIA cases without known lung disease from the International Childhood Arthritis Genetics Consortium (INCHARGE) genome-wide association study[2].

[4]European ancestry, matched by principal component analysis (see Methods and Figure S2 in Supplementary Appendix)

[5]sJIA with DHR, with and without DLD
significant: After correction for multiple comparisons, a statistically significant association in part A is p <3.07E-04.
[6]Drug tolerant sJIA: sJIA controls with ≥1 year of uneventful exposure to IL-1/IL-6 inhibitors
[7]Self-identified ancestry
[8]sJIA with DHR, with and without DLD, plus KD with suspected anakinra reaction (sAR)
[9]sJIA controls with ≥1 year of uneventful exposure to IL-1/IL-6 inhibitors and KD controls without features of DHR during anakinra
[10]All subjects, regardless of self-identified ancestry
[11]*HLA-DRB1*15:01+ HLA-DRB1*15:03+ HLA-DRB1*15:06*